Magazine

A novel mode of action to promote antibiotic-sparing approach to Recurrent UTIs: Questions and Answers on Clinical Practice1

Consultations for recurrent urinary tract infections (rUTIs) in everyday clinical practice range from 1% to 6% of all medical visits with high social and personal associated costs, such as prescriptions, hospital expenses, days of sick leave due to the disease, and the treatment of related comorbidities. Often urologists are asked to give practical recommendations to patients regarding the everyday management of recurrent UTIs. A new review1 aims to give to the physicians managing UTI some helpful suggestions for their everyday clinical practice, based on the recent evidence.

We are happy to announce the publication of new evidence on the benefit of an antibiotic-free approach (xyloglucan, hibiscus and propolis for oral administration) in the management of uncomplicated urinary tract infections.

Let’s celebrate 2022 with a new paper on Utipro® Plus and Utipro® Plus AF!! We are pleased to announce the publication of a meta-analysis in which the benefit of the combination of a mucoprotectant (xyloglucan or an equivalent substance), hibiscus and propolis in the management of uncomplicated urinary tract infections has been evaluated. Among different available publications, three of them were integrated into the final analysis leading the authors to interesting conclusions: “In the era of antibiotic resistance, an antibiotic-sparing approach presents an interesting alternative treatment of uncomplicated cystitis in women…“ and “A medical device containing xyloglucan, hibiscus and propolis is superior to comparator regimens in terms of clinical effectiveness in adult women with microbiologically confirmed or clinical suspicion of uncomplicated cystitis and is associated with a high patient compliance”, thus reinforcing the usefulness of Utipro® Plus/Utipro® Plus AF in acute and recurrent uncomplicated UTIs.